Jaime Rosenberg

Healthcare Editor

Portfolio
AJMC
Tumor Mutational Burden Predicts Who Will Respond to Immunotherapy

The advent of immunotherapy has significantly shifted the treatment paradigm and prognosis for multiple advanced-stage cancers. In cancers like metastatic melanoma and non-small cell lung cancer (NSCLC), the treatment class has greatly improved survival rates. However, not all patients respond to the treatments, highlighting the need for predictive biomarkers to determine which patients will benefit.

AJMC
Carfilzomib Regimen Results in Longer Time to Next Treatment, Improved Survival in RRMM

With the introduction of new classes of drugs in recent years, including immunomodulatory drugs and proteasome inhibitors, the multiple myeloma (MM) treatment landscape has shifted and improved rapidly, with response rates increasing from approximately 30% with single agents to approximately 90% with triplet combination regimens for newly diagnosed patients.

AJMC
Should Everyone Have Their Genome Sequenced at Birth?

Genomic sequencing at birth has the potential to shift the healthcare system from reactive to preventive and save countless lives in the process, but healthcare systems aren't ready for widespread implementation of these tests, according to a panel discussion at the World Economic Forum Annual Meeting in Davos, Switzerland.

AJMC
Positive Larotrectinib Study Results Highlight Importance of Molecular Profiling of Tumors

Recent study results showed larotrectinib was effective in patients with tropomyosin receptor kinase fusion-positive cancer, regardless of the age of the patient or the tumor type. In addition to implications for the treatment of genetic alterations across tumor types, these study results underscore the importance of molecular profiling of tumors, through which patients were identified for the studies, on ensuring precision medicine is used in practice while simultaneously providing a...

AJMC
FDA Approves Ibrutinib Combination as Frontline Treatment for CLL

The FDA has approved ibrutinib (Imbruvica) in combination with obinutuzumab for treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Ibrutinib is a first-in-class, once-daily inhibitor of Bruton's tyrosine kinase approved in 2016 as a single-agent, chemotherapy-regimen for patients with CLL.

Twitter icon Linkedin icon